Benin vs Guatemala: Average cost of drugs for extensively drug-resistant tuberculosis
Benin
6,274 constant 2022 US$
in 2024
Guatemala
11,910 constant 2022 US$
in 2024
Benin rank
6th
Guatemala rank
3rd
Average cost of drugs for extensively drug-resistant tuberculosis over time
- Benin
- Guatemala
How they compare
Guatemala currently reports 11,910 constant 2022 US$ against 6,274 constant 2022 US$ in Benin, a difference of 5,636 constant 2022 US$.
That makes Guatemala's figure about 1.9 times Benin's.
The two have swapped places 2 times across 6 shared years of data; in 2019 it was Guatemala ahead.
Benin ranks 6th and Guatemala ranks 3rd of 56 countries.
Across the 2 decades both report, Benin averaged higher in 1 and Guatemala in 1.
Head to head by decade
| Decade | Benin | Guatemala | Difference | Ahead |
|---|---|---|---|---|
| 2010s | 5,550 constant 2022 US$ | 11,075 constant 2022 US$ | 5,525 constant 2022 US$ | Guatemala |
| 2020s | 6,274 constant 2022 US$ | 5,989 constant 2022 US$ | 284.8 constant 2022 US$ | Benin |
Averages of every year both report within each decade.
Frequently asked questions
- Which has higher average cost of drugs for extensively drug-resistant tuberculosis, Benin or Guatemala?
- Guatemala, at 11,910 constant 2022 US$ against 6,274 constant 2022 US$ in Benin as of 2024.
- What is the difference in average cost of drugs for extensively drug-resistant tuberculosis between Benin and Guatemala?
- 5,636 constant 2022 US$, with Guatemala ahead.
- How many years of comparable data are there for Benin and Guatemala?
- 6 years are reported by both, from 2019 to 2024.
- How do Benin and Guatemala rank globally for average cost of drugs for extensively drug-resistant tuberculosis?
- Benin ranks 6th and Guatemala ranks 3rd of 56 countries.
- Where does this data come from?
- WHO (2025) – with minor processing by Our World in Data, published as Average cost of drugs for extensively drug-resistant tuberculosis. Statizoid refreshes it automatically from the source and publishes the full history for both places.
Individual pages
About this data
Average cost of drugs spent per patient starting extensively drug-resistant tuberculosis treatment, excluding buffer stock.